College of Medicine
Castillo Lab
Led by Paul Castillo · Pediatrics
What we study
Dr. Castillo's lab studies how to improve CAR T cell therapy for treating osteosarcoma and other cancers by boosting immune responses. They focus on systemic RNA vaccination and enhancing CAR T cell activity.
What working here is like
- Wet lab
- Projects
- 3
- Papers
- 5
Current projects
Rational tuning of CAR T cells against osteosarcoma for enhanced activity and reduced toxicity
Improving CAR T cell therapy for osteosarcoma by optimizing immune responses.
Unlocking CAR T cells Activity Against Metastatic Osteosarcoma Using Systemic RNA Vaccination
Using RNA vaccines to boost CAR T cell activity against metastatic osteosarcoma.
Show 1 more projectsShow fewer
Enhancing CD70 CAR T cell Homing to Acute Myeloid Leukemic Sites Leveraging Chemokine Signaling
Improving CAR T cell targeting to acute myeloid leukemia sites using chemokine signaling.
Summaries are written by AI in plain language from public symposium abstracts and may be imperfect.
Recent papers, explained
- 8R-70CAR T-Cells for Acute Myeloid Leukemia: Harnessing Cytokine Gradients for More Effective Cellular Therapy
2026 · Transplantation and Cellular Therapy
- Upper and Lower Respiratory Tract Compartmentalization in Pediatric Stem Cell Transplantation
2026 · American Journal of Respiratory Cell and Molecular Biology
Compares microbiome and gene expression changes in nasal and lung samples from pediatric transplant patients.
Show 3 more papersShow fewer
- A Survey of Provider Practices for Diagnosis and Treatment of Pediatric Moderate Aplastic Anemia From the North American Pediatric Aplastic Anemia Consortium
2026 · Journal of Pediatric Hematology/Oncology
Surveys diagnostic and treatment practices for pediatric moderate aplastic anemia.
- Prolonged Cytopenia After Idecabtagene Vicleucel for Multiple Myeloma is Associated with Poor Overall Survival
2026 · Transplantation and Cellular Therapy
Links prolonged cytopenia after CAR-T therapy to poor survival in multiple myeloma patients.
- Clinical risk factors alone do not predict the development of moderate-severe chronic graft-versus-host disease after hematopoietic cell transplantation and post-transplant cyclophosphamide
2026 · Bone Marrow Transplantation
Plain-language summaries are AI-written and reviewed by us; check the paper for details.
How to reach out
Paul Castillo hasn't set up this page yet. Their UF Scholars profile lists their publications.